Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Key Points

• Short interest rose 29.9% in January to 21,688,567 shares — about 6.3% of the stock — with a days-to-cover ratio of 2.9 based on average daily volume.
• Shares trade near $0.27 with a market cap of $93.17M, a 52‑week range of $0.08–$1.88 and a high beta (7.46), signaling pronounced volatility.
• Analyst/institutional context: Weiss Ratings reissued a "Sell" and MarketBeat shows a consensus Sell, while institutional ownership remains minimal (~0.43%) despite some recent small purchases.

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 21,688,567 shares, an increase of 29.9% from the January 15th total of 16,695,670 shares. Based on an average daily volume of 7,462,617 shares, the days-to-cover ratio is currently 2.9 days. Approximately 6.3% of the shares of the stock are sold short. Approximately 6.3% of the shares of the stock are sold short. Based on an average daily volume of 7,462,617 shares, the days-to-cover ratio is currently 2.9 days.

Incannex Healthcare Stock Up 0.0%

Shares of IXHL opened at $0.27 on Monday. The company has a market capitalization of $93.17 million, a price-to-earnings ratio of -0.46 and a beta of 7.46. Incannex Healthcare has a 52-week low of $0.08 and a 52-week high of $1.88. The stock has a 50 day moving average price of $0.36 and a 200 day moving average price of $0.42.

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) last issued its quarterly earnings data on Friday, February 13th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Incannex Healthcare in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of "Sell".

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. AdvisorShares Investments LLC lifted its position in Incannex Healthcare by 16.6% during the 2nd quarter. AdvisorShares Investments LLC now owns 343,954 shares of the company's stock worth $74,000 after acquiring an additional 48,920 shares during the period. Abacus Wealth Partners LLC acquired a new stake in shares of Incannex Healthcare in the third quarter valued at about $116,000. Arete Wealth Advisors LLC purchased a new stake in shares of Incannex Healthcare during the 3rd quarter worth approximately $547,000. Virtu Financial LLC acquired a new stake in Incannex Healthcare in the third quarter valued at $187,000. Finally, LPL Financial LLC increased its holdings in Incannex Healthcare by 639.1% during the 4th quarter. LPL Financial LLC now owns 335,373 shares of the company's stock valued at $120,000 after acquiring an additional 290,000 shares in the last quarter. 0.43% of the stock is currently owned by institutional investors and hedge funds.

Incannex Healthcare Company Profile

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company's research and development pipeline includes multiple product candidates in various stages of clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.